BioNTech/Pfizer virus vaccine promising in second trial, Study reveals

*Experimental vaccine induces virus-neutralising antibodies in previous trials

*Britain signs deals to secure 90 million doses of Pfizer/BioNTech vaccine, another

Isola Moses | ConsumerConnect

As scientists intensify efforts at producing a safe and effective vaccine to combat the fatal Coronavirus disease (COVID-19), German biotech BioNTech and United States (US) manufacturer Pfizer Incorporated have disclosed that data from an early-stage trial of their experimental virus vaccine showed that it prompted an immune response.

The companies Monday, July 20, 2020, said that the trial vaccine was well-tolerated, similar to results seen in prior early test, according to agency report.

It was learnt that in the study conducted in Germany on 60 healthy volunteers, the vaccine induced virus-neutralising antibodies in those given two doses, in-line with previous results from an early-stage US trial.

Reuters reports that under expedited development plans, the companies have stated that they expect to begin a trial later this month with up to 30,000 subjects with the aim of demonstrating the vaccine’s efficacy.

In the German study, the vaccine also generated a high level of T cell responses against the Coronavirus.

T cells, a type of white blood cell, are an important component of the immune system’s attack against foreign invaders, such as viruses.

Mizuho analyst Vamil Divan said of the positive development: “Today’s data includes the first evidence of the vaccine generating a T-cell response, which could be critical in order for patients to develop durable immunity to the novel Coronavirus.”

Report indicates that trial subjects experienced no serious side-effects from the vaccine, though some reported flu-like symptoms and injection site reactions.

The results come as separate results were released for two other experimental COVID-19 vaccines Monday.

AstraZeneca’s vaccine being developed with Oxford University researchers appeared to be safe and produced an immune response in early-stage clinical trials, report said. Another vaccine being developed by CanSino Biologics Inc and China’s military research unit also appeared to be safe and induced immune responses in most recipients.

More than 150 potential coronavirus vaccines are in various stages of development around the world, with 23 candidates already being tested in people, according to the World Health Organisation (WHO).

Meanwhile, Britain separately on Monday signed deals to secure 30 million doses of the Pfizer/BioNTech vaccine, as well for 60 million additional doses from French group Valneva.

Business Secretary Alok Sharma said the country would then have access to three different types of vaccines being developed domestically and around the world.

It has also launched a Web site for volunteers to sign up for vaccine studies.

Sharma stated that “the hunt to find a vaccine is a truly global endeavour and we are doing everything we can to ensure the British public get access to a safe and effective coronavirus vaccine as soon as possible.”

Kindly Share This Story